Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Result of AGM

27 Nov 2019 16:23

RNS Number : 9013U
Genedrive PLC
27 November 2019
 

genedrive plc

("genedrive" or the "Company")

 

Result of AGM

 

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that at the Annual General Meeting, held today, all resolutions proposed were duly passed.

 

For information, details of the proxy voting are shown below:

 

 Resolution

Votes For

Votes For (as % of votes cast)

Votes Against

Votes Against (as % of votes cast)

Votes Withheld

1. Receive the Annual report and accounts for the Company

22,673,789

100.0%

0

0.00%

515

2. Approve the Directors' Remuneration Report

21,886,545

96.5%

787,131

3.47%

628

3. Re-appoint Tom Lindsay as a director

22,674,304

100.0%

0

0.00%

0

4. Re-appoint Chris Yates as a director

22,674,304

100.0%

0

0.00%

0

5. Re-appoint David Budd as a director

22,674,304

100.0%

0

0.00%

0

6. Re-appoint Matthew Fowler as a director

22,674,304

100.0%

0

0.00%

0

7. Re-appoint Ian Gilham as a director

21,887,370

100.0%

314

0.00%

786,620

8. Appoint RSM UK as auditors of the Company

22,674,304

100.0%

0

0.00%

0

9. Directors' authority to allot shares

22,109,087

100.0%

0

0.00%

565,217

10. Disapplication of pre-emption rights

19,551,681

88.4%

2,556,891

11.57%

565,732

 

The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the Company's website (www.genedriveplc.com).

 

- Ends -

 

For further details please contact:

 

genedrive plc

www.genedriveplc.com

David Budd: CEO / Matthew Fowler: CFO

+44 (0)161 989 0245

 

 

 

 

Peel Hunt LLP

+44 (0)20 7418 8900

James Steel / Oliver Jackson

 

 

 

Stanford Capital Partners Limited

+44 (0)20 3815 8880

Patrick Claridge / John Howes

 

 

 

Walbrook PR Ltd (Media Relations & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

 

Notes to Editors

 

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® mt-RNR1-ID kit has received CE-IVD Certification and will be launched into Europe and other markets following full evaluation by the UK National Health Service. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGBLBDBGDDBGCR

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.